ArticleAnnals of clinical and translational neurology2025
Genetic Profile and Symptom Pattern Explain Variability of Deep Brain Stimulation Effect in Dystonia.
Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Etiologies of Dystonia with Anarthria/Aphonia.Movement disorders clinical practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveBilateral globus pallidus pars interna deep brain stimulation (GPi-DBS) is a recognized and effective treatment option for drug-resistant dystonia patients. However, the clinical GPi-DBS outcomes vary significantly. Herein, we explored the pre-implant factors affecting GPi-DBS effectiveness.
methodsGenetic profiles, symptom distribution, age at onset, disease duration, and severity of a cohort of 31 GPi-DBS dystonia patients were collected. Dystonia motor severity was evaluated before and after GPi-DBS using the Burke-Fahn-Marsden Dystonia-Rating-Scale (BFMDRS-M). We assessed the interplay of the aforementioned factors in determining the BFMDRS-M improvement through a multilinear regression analysis.
resultsBFMDRS-M score showed a significant improvement (47.8%) since the first year, remaining stable at 5 years (54.3%). Lower limb (0.20), upper limb (0.16) and trunk (0.24) symptoms showed a significantly larger improvement compared to cranial symptoms (0.07, p < 0.05). Consequently, patients with more pronounced lower limb motor symptoms displayed a greater GPi-DBS effect (p < 0.01). However, pre-treatment localization of motor symptoms accounted only for 31% of the Inter-Patient Variability (IPV) in post-GPi-DBS improvement. Amelioration varied also across genetic profiles, with the largest improvement reported for DYT-TOR1A patients (n = 9, 64.2% in the first year), predicting 36% of IPV. Interestingly, combining motor and genetic profiles predicted 73% of the IPV. Including the clinical profile of the patient (age at onset, disease severity and duration) increased prediction accuracy to 81%.
interpretationOur results suggest that motor and genetic profiles contribute independently to the efficacy of the GPi-DBS treatment. These results may support a personalized prediction of DBS outcomes in dystonia patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.